Sab Biotherapeutics Inc (SABS): Hedge Fund Ownership & Smart Money Signals (Q1 2026)

Q: Is it too late to buy Sab Biotherapeutics Inc (SABS) following the 2026 Q1 hedge fund 13F filings?

As of today, SABS has moved +8.1% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.0% for the XLV sector ETF — an outperformance of +5.1%. Since the quarter end (March 31, 2026), SABS gained +4.4% vs +1.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Sab Biotherapeutics Inc (SABS)

76 + Investors. Track Smart Money conviction in SABS. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — SABS

Based on 76 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q

For 3 consecutive quarters, more hedge funds added SABS than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

76 hedge funds hold SABS right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +192% more funds vs a year ago

fund count last 6Q

+50 new funds entered over the past year (+192% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟢

More buyers than sellers — 83% buying

59 buying12 selling

Last quarter: 59 funds were net buyers (34 opened a brand new position + 25 added to an existing one). Only 12 were sellers (6 trimmed + 6 sold completely). A clear majority buying is a strong confirmation signal.

📈

More new buyers each quarter (+13 vs last Q)

new funds entering per quarter

Funds opening a new SABS position: 3 → 13 → 21 → 34. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

🔄

Mostly new holders — 63% entered in last year

■ 24% conviction (2yr+) ■ 13% medium ■ 63% new

Only 18 funds (24%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

🚀

Acceleration phase — new buyers rushing in

4 → 3 → 13 → 21 → 34 new funds/Q

New funds entering each quarter: 3 → 13 → 21 → 34. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.

🌱

Early stage — 57% of holders entered in last year

■ 39% veterans ■ 4% 1-2yr ■ 57% new

Of 80 current holders: 46 (57%) entered in the past year, only 31 (39%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.

📋

Smaller funds dominant — 8% AUM from top-100

8% from top-100 AUM funds

15 of 73 holders rank in the top 100 by AUM, but together hold only 8% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

6.6

out of 10

Moderate Exit Risk

Exit risk score 6.6/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	76	48	58.33%
13F Shares	70M	36M	92.0%
Total Value	$267M	$136M	96.57%
New Positions	34	21	+13
Increased Positions	25	11	+14
Closed Positions	6	7	-1
Reduced Positions	6	4	+2
Total Calls	3	0	100%
Total Puts	3	0	100%
PUT/CALL Ratio	1.0	0.0	Neutral

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

58.33%

13F Shares

70M

36M

92.0%

Total Value

$267M

$136M

96.57%

New Positions

+13

Increased Positions

+14

Closed Positions

-1

Reduced Positions

Total Calls

100%

Total Puts

100%

PUT/CALL Ratio

1.0

0.0

Neutral

Institutional Holders (2026 Q1)

76 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in SABS. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 SABS holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Vivo Capital, LLC	3.65%	11,420,000	$43.7M
2	Propel Bio Management, LLC	2.45%	1,012,790	$3.9M
3	Caligan Partners LP	2.03%	7,967,207	$30.5M
4	Spruce Street Capital LP	2.02%	2,198,502	$8.4M
5	Monashee Investment Management LLC	1.04%	500,000	$1.9M
6	Commodore Capital LP	0.98%	4,401,500	$16.9M
7	Seven Fleet Capital Management LP	0.49%	400,000	$1.5M
8	Perceptive Advisors LLC	0.48%	6,431,743	$24.6M
9	Stempoint Capital LP	0.28%	375,000	$1.4M
10	Fifth Lane Capital, LP	0.22%	46,500	$178K
11	Ra Capital Management, L.P.	0.18%	4,401,500	$16.9M
12	AWM Investment Company, Inc.	0.17%	400,000	$1.5M
13	Soleus Capital Management, L.P.	0.16%	1,050,000	$4.0M
14	Sessa Capital IM, L.P.	0.15%	2,198,457	$8.4M
15	Seven Fleet Capital Management LP	0.12%	100,000	$383K
16	Affinity Asset Advisors, LLC	0.11%	575,000	$2.2M
17	Persistent Asset Partners Ltd	0.10%	69,732	$267K
18	Stonepine Capital Management, LLC	0.08%	50,000	$192K
19	Boothbay Fund Management, LLC	0.07%	1,481,660	$5.7M
20	Seven Grand Managers, LLC	0.07%	275,000	$1.1M
21	Woodline Partners LP	0.04%	2,851,791	$10.9M
22	DV Trading LLC	0.04%	400,000	$1.5M
23	Scientech Research LLC	0.03%	10,816	$41K
24	ExodusPoint Capital Management, LP	0.02%	768,627	$2.9M
25	Miller Capital Partners, Inc.	0.02%	12,870	$49K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Sab Biotherapeutics Inc (SABS)

What does the Smart Money Trend signal show for SABS?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added SABS than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for SABS?

More buyers than sellers — 83% buying: Last quarter: 59 funds were net buyers (34 opened a brand new position + 25 added to an existing one). Only 12 were sellers (6 trimmed + 6 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for SABS holders?

Smaller funds dominant — 8% AUM from top-100: 15 of 73 holders rank in the top 100 by AUM, but together hold only 8% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held SABS?

Mostly new holders — 63% entered in last year: Only 18 funds (24%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Sab Biotherapeutics Inc (SABS) following the 2026 Q1 hedge fund 13F filings?

As of today, SABS has moved +8.1% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.0% for the XLV sector ETF — an outperformance of +5.1%. Since the quarter end (March 31, 2026), SABS has gained +4.4% vs +1.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Sab Biotherapeutics Inc (SABS)

Smart Money Signals — SABS

Buying streak — 3 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +192% more funds vs a year ago

More buyers than sellers — 83% buying

More new buyers each quarter (+13 vs last Q)

Mostly new holders — 63% entered in last year

Acceleration phase — new buyers rushing in

Early stage — 57% of holders entered in last year

Smaller funds dominant — 8% AUM from top-100

Institutional Sentiment Summary — SABS

Hedge Fund Ownership: SABS

Market Analysis: SABS

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: SABS

Is It Too Late to Buy Sab Biotherapeutics Inc (SABS) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: SABS

Statistics: SABS

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q1)

Frequently Asked Questions — Sab Biotherapeutics Inc (SABS)

Welcome to 13Foresight!